Effects of the Addition and Subtraction of Zhenggan Huazheng Tang Together with Western Drug Therapy on Liver Function and T Lymphocyte Subpopulations in Patients with Primary Hepatocellular Carcinoma
Objective To explore the application effect of the addition and subtraction of Zhenggan Huazheng Tang to-gether with western medicines(Capecitabine+Lenvatinib mesylate+Oxaliplatin)in the treatment of patients with Primary Liver Cancer(PLC).Methods 68 patients with PLC were retrospectively selected according to the matching principle for the study,they were divided into control group and observation group,with 34 cases in each group according to different treatment schemes.Among them,those who were treated with Capecitabine+Lenvartinib mesylate were included in the control group,and those who were treated with Zhenggan Huazheng Decoction plus Capecitabine+Lenvartinib mesylate were included in the ob-servation group.Objective remission rates were compared between the two groups,as well as the levels of liver function indi-cators[alkaline phosphatase(ALP),total bilirubin(TBIL)],T lymphocyte subsets(CD3+,CD4+/CD8+),and tumor markers[vimentin(VIM),alpha fetoprotein(AFP),Golgi protein 73(GP73)]before treatment,after 2 and 4 courses of treatment,and the occur-rence of toxic side effects was also compared between the two groups.Results The objective remission rate of the observa-tion group(64.71%)was higher than that of the control group(35.29%)(P<0.05);after 2 and 4 courses of treatment,the levels of ALP and TBIL in the observation group were lower than those in the control group(P<0.05);the levels of CD3+,CD4+/CD8+in the observation group were higher than those in the control group after 2 and 4 courses of treatment(P<0.05);the levels of VIM,AFP and GP73 in the observation group were lower than those in the control group after 2 and 4 courses of treatment(P<0.05);compared with the control group,there was no significant difference in the incidence of various toxic and side effects in the observation group(P>0.05).Conclusion Zhenggan Huazheng Decoction combined with Capecitabine+Lenvatinib mesylate in the treatment of PLC patients can effectively improve the objective remission rate of the disease,re-duce the damage of liver function and immune function,delay the progression of the disease,and is safe and reliable.
国家科技期刊平台
NSTL
万方数据
